Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

DSpace Repository

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

Author: Long, Georgina V.; Stroyakovskiy, Daniil; Gogas, Helen; Levchenko, Evgeny; de Braud, Filippo; Larkin, James; Garbe, Claus; Jouary, Thomas; Hauschild, Axel; Grob, Jean-Jacques; Chiarion-Sileni, Vanna; Lebbe, Celeste; Mandala, Mario; Millward, Michael; Arance, Ana; Bondarenko, Igor; Haanen, John B. A. G.; Hansson, Johan; Utikal, Jochen; Ferraresi, Virginia; Kovalenko, Nadezhda; Mohr, Peter; Probachai, Volodymr; Schadendorf, Dirk; Nathan, Paul; Robert, Caroline; Ribas, Antoni; DeMarini, Douglas J.; Irani, Jhangir G.; Swann, Suzanne; Legos, Jeffrey J.; Jin, Fan; Mookerjee, Bijoyesh; Flaherty, Keith
Tübinger Autor(en):
Garbe, Claus
Published in: Lancet (2015), Bd. 386, H. 9992, S. 444-451
Verlagsangabe: Elsevier Science Inc
Language: English
Full text: http://dx.doi.org/10.1016/S0140-6736(15)60898-4
ISSN: 0140-6736
DDC Classifikation: 610 - Medicine and health
Dokumentart: Artikel
Show full item record

This item appears in the following Collection(s)